2F-QMPSB

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
2F-QMPSB
2F-QMPSB structure.png
Identifiers
ChemSpider
Chemical and physical data
FormulaC22H20F2N2O4S
Molar mass446.467 g·mol−1
3D model (JSmol)

2F-QMPSB (SGT-13) is an arylsulfonamide-based synthetic cannabinoid that is a fluorinated derivative of QMPSB and has been sold as a designer drug. Its identification was first reported by a forensic laboratory in Italy in January 2019,[1] and it was made illegal in Latvia shortly afterwards.[2][3] Fluorination of the tail group is a common strategy to increase potency at cannabinoid receptors which is seen in many related series of compounds.[4][5]

See also[edit]

References[edit]

  1. ^ "NPS2019". Belgian Early Warning System on Drugs (BEWSD).
  2. ^ Centre for Disease Prevention and Control (17 January 2019). "Par aizlieguma noteikšanu vielai 2F-QMPSB un tās saturošiem izstrādājumiem" [On the Prohibition of 2F-QMPSB and Articles Containing It]. Latvian Journal: Legal Acts of the Republic of Latvia (in Latvian).
  3. ^ "Уважаемые эксперты" [Dear experts]. Aipsin Drugs (in Russian).
  4. ^ Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, et al. (August 2015). "Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chemical Neuroscience. 6 (8): 1445–58. doi:10.1021/acschemneuro.5b00107. PMID 25921407.
  5. ^ Yang SW, Smotryski J, Matasi J, Ho G, Tulshian D, Greenlee WJ, et al. (January 2011). "Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain". Bioorganic & Medicinal Chemistry Letters. 21 (1): 182–5. doi:10.1016/j.bmcl.2010.11.044. PMID 21115245.